货号:A257865 同义名: Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 2;PD-1/PD-L1 inhibitor 2
BMS-202 是一种有效的非肽类 PD-1/PD-L1 复合物抑制剂,IC50 为 18 nM,KD 为 8 μM。BMS-202 通过直接结合 PD-L1 阻断人类 PD-1/PD-L1 的相互作用,具有抗肿瘤活性。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | PD-1 ↓ ↑ | PD-1/PD-L1 ↓ ↑ | PD-1/PD-L1 interaction ↓ ↑ | PD-L1 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SR0987 | ✔ | 98% | |||||||||||||||||
Pembrolizumab | ✔ | 98% | |||||||||||||||||
Camrelizumab | ✔ | 5mg/mL | |||||||||||||||||
Spartalizumab | ✔ | 95% | |||||||||||||||||
BMS-1001 |
+
PD-1/PD-L1, EC50: 253 nM |
+
PD-1/PD-L1, EC50: 253 nM |
98% | ||||||||||||||||
INCB086550 |
++
PD-1/PD-L1, IC50: <10 nM |
++
PD-1/PD-L1, IC50: <10 nM |
98% | ||||||||||||||||
BMS-1 |
++
PD-1/PD-L1 interaction, IC50: 0.006 μM |
99%+ | |||||||||||||||||
BMS-202 |
+
PD-1/PD-L1 interaction, IC50: 0.018 μM |
99%+ | |||||||||||||||||
PD-1/PD-L1-IN 3 |
+++
PD-1/PD-L1 interaction, IC50: 5.6 nM |
98+% | |||||||||||||||||
Nivolumab |
+++
PD-1/PD-L1 interaction, IC50: 2.52 nM |
95% | |||||||||||||||||
BMS-1166 |
+++
PD-1/PD-L1 interaction, IC50: 1.4 nM |
99%+ | |||||||||||||||||
Durvalumab |
++++
PD-1/PD-L1 interaction, IC50: 0.1 nM |
95% | |||||||||||||||||
Evixapodlin |
++++
PD-1/PD-L1, IC50: 0.213 nM |
95% | |||||||||||||||||
CA-170 | ✔ | 97% (contains 2.7% ethanol) | |||||||||||||||||
Atezolizumab |
+++
hPD-L1, Kd: 0.4 nM |
98% | |||||||||||||||||
AUNP-12 | ✔ | 99% | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | BMS-202 is identified as a potent and nonpeptidic inhibitor of the PD-1/PD-L1 complex, demonstrating an IC50 of 18 nM and a KD of 8 μM. It binds to PD-L1, effectively preventing the interaction between human PD-1 and PD-L1, and exhibits antitumor capabilities[1].[2]. |
体内研究 | An antitumor effect is observed with BMS-202 treatment (20 mg/kg; intraperitoneal injection; daily for 9 days) in humanized MHC- dKO NOG mice, showing a significant reduction in tumor growth compared to control groups[2]. |
体外研究 | In vitro treatment with BMS-202 (0-100 μM for 4 days) on SCC-3 or Jurkat cells results in the inhibition of proliferation of PD-L1-high SCC-3 cells (IC50=15 μM) and anti-CD3 antibody-stimulated Jurkat cells (IC50=10 μM)[2]. BMS-202 selectively promotes thermal stabilization of PD-L1 and induces PD-L1 dimerization in solution. Located at the core of the homodimer, BMS-202 fills a deep hydrophobic pocket, enhancing interactions between monomers and making contact with both PD-L1 molecules through hydrophobic surfaces used in the PD-1/PD-L1 interaction[1]. |
Animal Administration | i.p. |
Dose | Mice: 20 mg/kg [1] (i.p.) |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.38mL 0.48mL 0.24mL |
11.92mL 2.38mL 1.19mL |
23.84mL 4.77mL 2.38mL |
CAS号 | 1675203-84-5 |
分子式 | C25H29N3O3 |
分子量 | 419.516 |
别名 | Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 2;PD-1/PD-L1 inhibitor 2 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
溶解度 |
DMSO: 105 mg/mL(250.29 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |